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The American College of Cardiology/American Heart As-
sociation (ACC/AHA) Guidelines for the Management of
Patients With Acute Myocardial Infarction have been
reviewed over the past 21⁄2 years since their initial publica-
tion (J Am Coll Cardiol 1996;28:1328–428) to ensure their
continued relevancy. The guidelines have been updated to
include the most significant advances that have occurred in
the management of patients with acute myocardial infarc-
tion (AMI) during that time frame. This Update was
developed to keep the guidelines current without republish-
ing them in their entirety. The Update represents a new
procedure of the ACC/AHA Task Force on Practice
Guidelines. These guidelines will be reviewed and updated
as necessary until it is deemed appropriate to revise and
republish the entire document.
This Update, as printed here in the Journal of the
American College of Cardiology, appears without the full text
guidelines. The full text guidelines, incorporating the
Update, are available on the Web sites of both the
American College of Cardiology (www.acc.org) and the
American Heart Association (www.americanheart.org).
In the Web site version, deleted text is indicated by
sytyryıykyeyoyuyty, and new/revised text is presented in a high-
lighted typeface. Reprints of the original 1996 document
with the revised sections appended are available from
both organizations (see footnote).
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This Update is presented in 4 sections as follows:
1. Changes/additions to text
2. New and revised figures and tables
3. Changes in Class I, II, and III recommendations
4. Changes in references
This Update to the guidelines represents a new proce-
dure. Comments about this approach and format are en-
couraged and should be sent to Chair, ACC/AHA Task
Force on Practice Guidelines, American College of Cardi-
ology, 9111 Old Georgetown Road, Bethesda, MD 20814.
New section, page 1340, column 2: new text replaces
paragraphs beginning “An ideal serum marker . . .”
through page 1342, column 1, “Assays for biochemical . . .”
Serum cardiac markers. When myocytes become necrotic,
they lose membrane integrity, and intracellular macromol-
ecules diffuse into the cardiac interstitium and ultimately
into the cardiac microvasculature and lymphatics (55).
Eventually, these macromolecules are detectable in the
peripheral circulation. The term currently used to collec-
tively describe these macromolecules is serum cardiac mark-
ers. An ideal serum cardiac marker of MI should be present
early and in high concentration in the myocardium and
should be absent from nonmyocardial tissue and serum
(55–57). It should be rapidly released into the blood at the
time of the myocardial injury, and there should be a
stoichiometric relation between the plasma level and the
extent of myocardial injury. The marker should persist in
blood for a sufficient length of time to provide a convenient
diagnostic time window. Finally, measurement of the
marker should be easy, inexpensive, and rapid.
The nomenclature of the acute coronary syndromes
(ACS) is illustrated in revised Figure 2. The central position
of the 12-lead electrocardiogram (ECG) and initial triage of
patients are emphasized. Listed at the bottom of the figure
is the information sought by clinicians when measuring
serum cardiac marker levels in patients at different ends of
the ACS spectrum. Serum cardiac markers are useful for
confirming the diagnosis of MI when patients present
without ST-segment elevation, when the diagnosis may be
unclear, and when clinicians must distinguish patients with
unstable angina from those with a non–Q-wave MI. Serum
cardiac markers also provide valuable prognostic informa-
tion. For patients with ST-segment elevation, the diagnosis
of MI is secure; clinicians are interested in prognostic
information as well as a noninvasive assessment of the
likelihood that the patient has undergone successful reper-
fusion when thrombolytic therapy is administered.
Because the conventional serum cardiac marker, creatine
kinase (CK) and its MB isoenzyme (CK-MB) lack sufficient
sensitivity and specificity, there is a need for more sensitive
and cardiac-specific markers of myocardial necrosis (792–
794). The troponin complex consists of 3 subunits: troponin
T, troponin I, and troponin C (795). The ternary troponin
complex is a calcium-sensitive molecular apparatus that
regulates the interaction of actin and myosin. Troponin T
binds the troponin complex to tropomyosin, and troponin I
binds to actin and inhibits interactions between actin and
myosin. Troponin C is responsive to changes in intracellular
calcium concentration. Amino acid sequences of the skeletal
and cardiac isoforms of troponin I and troponin T have
sufficient dissimilarity that monoclonal antibody-based im-
munoassays have been developed to detect cardiac-specific
troponin T (cTnT) and cardiac-specific troponin I (cTnI).
Because the amino acid sequence of troponin C is the same
in cardiac and skeletal muscle, no immunoassays of troponin
C have been developed for clinical purposes.
Because CK-MB is found in the skeletal muscle and
blood of healthy subjects, the cutoff value for an elevated
CK-MB level is typically set a few units above the upper end
of the reference (normal) range. In contrast, because cardiac
troponin I and cardiac troponin T are not normally detected
in the blood of healthy people, the cutoff value for elevated
cTnI and cTnT levels may be set only slightly above the
noise level of the assay, permitting clinicians to diagnose
lesser degrees of myocardial necrosis (ie, increased sensitiv-
ity) (796). Because CK and CK-MB are characteristically
used as the gold standard for diagnosing MI, investigators
may face a dilemma when a new diagnostic test is more
sensitive than the gold standard, particularly for identifying
episodes of minor myocardial cell necrosis. Case reports
confirm histologic evidence of focal myocyte necrosis in
patients with elevated cardiac troponin levels and normal
Figure 2. Patients with ischemic discomfort may present with or
without ST-segment elevation on the electrocardiogram. The
majority (large arrow) of patients with ST-segment elevation
ultimately develop a Q-wave AMI, whereas a minority (small
arrow) develop a non–Q-wave AMI. Of patients who present
without ST-segment elevation, the majority (large arrows) are
ultimately diagnosed as having either unstable angina or non–Q-
wave AMI based on the presence or absence of a cardiac marker
such as CK-MB detected in the serum; a minority of such patients
ultimately develop a Q-wave AMI. The spectrum of clinical
conditions ranging from unstable angina to non–Q-wave AMI and
Q-wave AMI is referred to as acute coronary syndromes. AMI 5
acute myocardial infarction.
Adapted from Antman EM, Braunwald E. Acute myocardial
infarction. In: Braunwald EB, editor. Heart Disease: A Textbook
of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 1996.
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CK values (796). It is estimated that ’30% of patients
presenting without ST-segment elevation who would oth-
erwise be diagnosed with unstable angina are actually
experiencing a non–Q-wave MI when assessed with
cardiac-specific troponin assays (797). Furthermore, numer-
ous investigators have now reported that elevated levels of
cTnI or cTnT provide more prognostic information than
that supplied by the patient’s demographic characteristics or
the ECG at presentation (798,799). Elevated cTnI or cTnT
levels, even in the presence of normal CK-MB levels,
identify patients without ST-segment elevation who are at
an increased risk of death. Finally, patients presenting
without ST-segment elevation who are characterized as
high risk because of elevated cardiac-specific troponin levels
demonstrate a greater benefit from treatment with new
therapies such as glycoprotein (GP) IIb/IIIa inhibitors than
patients without elevated cardiac-specific troponin levels
who receive such new pharmacotherapeutic interventions
(800).
CK-MB isoforms are another new serum cardiac marker
that may be useful for evaluating patients with an acute
coronary syndrome. CK-MB exists in only 1 form in
myocardial tissue but in different isoforms (or subforms) in
the plasma. An absolute level of CK-MB2 .1 U/L or a ratio
of CK-MB2 to CK-MB1 of 1.5 has improved sensitivity and
specificity for diagnosis of MI within the first 6 hours
compared with conventional assays for CK-MB (59). Myo-
globin, a low-molecular-weight heme protein found in
cardiac and skeletal muscle, is not cardiac specific but is
released more rapidly from infarcted myocardium than
CK-MB and may be detected as early as 2 hours after MI.
The diagnostic sensitivity and specificity for MI were
compared for total CK-MB (activity and mass), CK-MB
subforms, myoglobin, cTnI, and cTnT in the Diagnostic
Marker Cooperative Study (DMCS) (801). The DMCS
was a large, prospective, multicenter, double-blind study of
patients presenting in the emergency department (ED) with
chest pain. CK-MB subforms were most efficient for early
diagnosis (within 6 hours) of MI, whereas cTnI and cTnT
were highly cardiac specific and particularly efficient for late
diagnosis of MI. The DMCS investigators concluded that
either a single assay (CK-MB subforms) or a select combi-
nation (CK-MB subform and a cardiac-specific troponin)
reliably triages patients with chest pain and could potentially
lead to improved therapy and reduced cost of care of ACS
patients. It should be noted that serum levels of cTnT and
cTnI may be present for several days after MI (up to 7 days
for cTnI and up to 10 to 14 days for cTnT). Therefore, the
ability to diagnose recurrent infarction is significantly com-
promised if the clinician relies solely on cardiac-specific
troponins and fails to obtain a concomitant CK or CK-MB
measurement within the first 12 to 24 hours of admission of
an MI patient. Thus, although CK and CK-MB are not as
cardiac specific as the troponins, they will return to normal
levels within the first 24 to 36 hours, making it more likely
that a reelevation is associated with recurrent myocardial
necrosis. For patients presenting within the first 2 or 3 hours
of symptom onset, the 2 markers most appropriate for the
early diagnosis of AMI are myoglobin and CK-MB sub-
forms.
In patients presenting with ST-segment elevation, clini-
cians usually use peak CK as a rough estimate of the
magnitude of the infarct and assessment of the patient’s
prognosis. Release of cardiac-specific troponins is stoichio-
metrically correlated with the amount of myocardial necro-
sis, and the new serum cardiac markers can also be used to
estimate infarct size and prognosis (58). Cardiac-specific
troponins may not be detectable for up to 6 hours after onset
of chest pain. Thus, when cTnI and cTnT levels are
elevated early after onset of discomfort in patients with
ST-segment elevation MI, clinicians should suspect that an
antecedent episode of unstable angina was in fact MI and
the patient is exhibiting a stuttering course of occlusion and
release of the infarct-related artery. Data from the Global
Utilization of Streptokinase and TPA for Occluded Arteries
(GUSTO) III Study suggest that patients with elevated
cardiac troponin T levels and who are ,6 hours from the
onset of discomfort have an increased mortality risk (802).
In addition to monitoring the patient for resolution of
ischemic-type chest discomfort and regression of the mag-
nitude of ST-segment elevation on the ECG, clinicians can
obtain serial measurements of serum cardiac markers to
buttress the noninvasive diagnosis of reperfusion of the
infarct-related artery after thrombolytic therapy (65,803).
Because of its rapid-release kinetics, myoglobin is a partic-
ularly attractive marker for the early diagnosis of reperfu-
sion.
New section: Follows “Serum Cardiac Markers” (see page
1340, column 2)
Bedside testing for serum cardiac markers. Handheld
rapid bedside assays are clinically available for measuring
cTnI, cTnT, myoglobin, and CK-MB. Small desktop rapid
analyzers are also available for the same purpose. A rapid,
high-voltage electrophoretic system is available for measur-
ing CK-MB isoforms. When using a handheld rapid
bedside assay for a serum cardiac marker, the clinician places
a small aliquot of the patient’s blood or serum in the
specimen well and observes the development of a colored
line in the read zone of the device. It should be noted that
the time to development of the colored line and the
intensity of the color are related to the concentration of the
serum cardiac marker in the specimen. For example, when a
handheld bedside immunoassay is used to test the blood of
patients with high cTnT levels, a red line quickly appears;
such patients are at increased mortality risk (804). Careful
attention to the timing of the appearance of a positive
bedside assay result may provide clinicians with a tool for a
semiquantitative estimate of a serum cardiac marker level at
the patient’s bedside. A positive bedside test, however,
should be confirmed by a conventional quantitative test.
892 Ryan et al. JACC Vol. 34, No. 3, 1999
1999 Update: Management of AMI September 1999:890–911
Text added to “Risk of Stroke,” page 1348, column 1: new
text added after paragraph beginning “Thrombolytic
therapy is associated with . . .”
More recent trials show that as use of thrombolysis has
increased, a greater proportion of patients who are .75
years old or female are now included. This change has been
associated with a higher rate of intracranial hemorrhage
(ICH) than that seen in earlier studies. For example, the
rate of ICH after administration of alteplase was ’0.7%; in
more recent studies, it is 0.8 to 0.9% (new Table 2.1). It
should be noted that the streptokinase without heparin
administration regimen has the lowest rate of ICH.
Text added to “Primary Percutaneous Transluminal
Coronary Angioplasty,” page 1351, column 1: new text
replaces paragraph beginning “A meta-analysis
suggests . . .”
In the GUSTO-IIb trial (805), 1138 patients with evolving
ST-segment elevation MI within 12 hours of onset of chest
pain were randomly assigned to receive primary percutane-
ous transluminal coronary angioplasty (PTCA) (n 5 565) or
accelerated tissue plasminogen activator (tPA) (n 5 573).
Thirty days after enrollment, the incidence of death, recur-
rent MI, or disabling stroke was 9.6% in those who
underwent PTCA and 13.6% in those who received tPA
(P 5 0.033). However, 6 months after enrollment the
difference between the 2 treatments did not reach statistical
significance; the incidence of the composite adverse out-
come was 13.3% in the PTCA group and 15.7% in the tPA
group (P 5 NS).
Recently published data from the Second National Reg-
istry of Myocardial Infarction (NRMI-2) (124) suggest that
primary PTCA and thrombolytic therapy offer similar
efficacy. Over 17 months, 4939 subjects with evolving
ST-segment elevation MI received primary PTCA, and
24,705 received alteplase. For patients without cardiogenic
shock, the in-hospital mortality rate was similar (5.4% for
the alteplase group, 5.2% for the PTCA group), and this
was true even when the data from certain “high-risk”
subgroups, such as those .75 years old and those with
anterior MI, were analyzed.
Among the most important contributions to these revised
guidelines are the data in the preliminary report of the
Should We Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock? (SHOCK) Trial, presented by Dr
Judith Hochman on March 7, 1999, at the 48th Scientific
Sessions of the American College of Cardiology, held in
New Orleans, Louisiana and to be published in the August
26, 1999 issue of the New Engl J Med (805a). When this
multicenter study was designed in 1992, it was postulated
that emergency revascularization (ERV) of cardiogenic
shock due to an ST-elevation/Q-wave or new left bundle-
branch block (LBBB) MI would result in a 20% (absolute)
reduction in the primary end point, all-cause 30-day mor-
tality compared with initial medical stabilization (IMS), and
delayed revascularization as clinically determined.
In this study, 152 patients were randomly assigned to the
ERV strategy, and 150 patients were assigned to a strategy
of IMS. The 30-day mortality rate for ERV patients was
46.7% versus 56.0% for IMS patients (95% confidence
interval [CI], 220.5 to 11.9%, P 5 0.11), a nonsignificant
trend. However, the mortality rate at 6 months (a secondary
end point) was significantly lower in the ERV group (50.3%
versus 63.1%, P 5 0.27). The prespecified subgroup analysis
of patients ,75 years old showed a 15.4% reduction in the
primary end point (IMS group, 56.8%, versus ERV group,
41.4%, P , 0.01), whereas outcome in patients .75 years old
was worse for the ERV group. Intra-aortic balloon pump
(IABP) support was used in 86% of both groups; 63% of the
IMS group received thrombolytic agents, and 25% underwent
delayed revascularization. Of the ERV group of patients who
underwent emergency early revascularization, ’60% received
PTCA, and 40% had coronary artery bypass graft (CABG);
the 30-day mortality rate was 45% and 42%, respectively.
New Table 2.1. Intracranial Hemorrhage in Recent Thrombolytic Trials
Patient Characteristics
GUSTO-I
(497)
GUSTO-II
(805)
COBALT
(832)
GUSTO-III
(802,833) ASSENT-2* In Time-II*
Number 41,021 3473 7169 15,059 16,950 15,078
Average age (y) 62 62.5 62.4 63 — —
.75 y (%) 10.5 11.8 13.0 13.6 — —
Female (%) 25.2 22.4 23.4 27.4 — —
Intracranial Hemorrhage Rates
SK 0.51 0.37 — — — —
tPA 0.70 0.72 Double bolus 1.12
Accl infusion 0.81
0.87 0.93 0.62
rPA — — — 0.91 — —
TNK-tPA 0.7 0.72 — — 0.94 —
nPA — — — — — 1.13
accl 5 accelerated, nPA 5 lanetoplase, rPA 5 reteplase, TNK-tPA 5 a genetically engineered variant of tPA, tPA 5 tissue plasminogen activator, SK 5 streptokinase.
*Data based on preliminary results.
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An early meta-analysis of the randomized clinical trials
that compared primary PTCA with thrombolytic therapy
was reported in early 1995 (121) and included data on
in-hospital or 6-week mortality and nonfatal MI for all 7
trials reported to that time. The combined data showed a
mortality rate at 6 weeks of 3.7% in the PTCA group and
6.4% in the thrombolysis group (odds ratio [OR], 0.56; 95%
CI, 0.33 to 0.94). In the combined outcome of short-term
mortality and nonfatal reinfarction, the event rate was 6.1%
for the PTCA group and 11.0% for the thrombolytic
therapy group (OR, 0.53; 95% CI, 0.35 to 0.80). By 1 year,
however, none of these end point differences were statisti-
cally significant. The analyses showed that ’30% of the
thrombolytic therapy patients underwent PTCA sometime
during hospitalization or within the first 6 weeks of infarc-
tion. Therefore, the contrast in the proportions of patients
receiving any PTCA versus patients receiving no PTCA was
substantial (64%). The authors conclude that the data on
primary PTCA appear promising but should be interpreted
with caution and viewed as a strong impetus for the
conduction of larger trials in a more diverse range of
hospitals, with clinical outcomes being the primary end
points of interest.
A more recent meta-analysis by Weaver et al (806)
provides a quantitative review of the treatment effects of
primary coronary angioplasty versus intravenous thrombol-
ysis for AMI from 10 randomized trials that involved 2606
patients. When the results of all studies were combined, the
mortality rate at #30 days was 4.4% for the 1290 patients
treated with primary angioplasty, compared with 6.5% for
the 1316 patients treated with thrombolysis (34% reduction;
OR, 0.66%; 95% CI, 0.46 to 0.94; P 5 0.02). The pooled
rate of death or nonfatal reinfarction was also lower in
patients treated with primary PTCA than in those treated
with thrombolytic therapy, from 11.9% to 7.2%, respectively
(OR, 0.58; 95% CI, 0.44 to 0.76). Angioplasty was associ-
ated with a significant reduction in total stroke (9/1290,
0.7%; versus 26/1390, 2%; P 5 0.007) and hemorrhagic
strokes as well (0.1% versus 1.1%; P , 0.001). On the basis
of outcomes at hospital discharge or 30 days, this analysis
concluded that “primary PTCA appears to be superior to
thrombolytic therapy for treatment of patients with AMI,
with the proviso that success rates for PTCA are as good as
those achieved in these trials. Data evaluating longer-term
outcome, operator expertise, and time delays before treat-
ment are needed before primary PTCA can be recom-
mended universally as the preferred treatment.” Recently
Brodie et al (788) pointed out that patients who underwent
angioplasty within 2 hours of onset of symptoms showed a
striking 53% relative reduction in 30-day mortality com-
pared with those who underwent angioplasty .2 to 6 hours
(4.3% versus 9.2%; P , 0.04). Because their data failed to
show an important time-dependent worsening of mortality
beyond 2 hours, it has been suggested that the time delay in
transferring patients with AMI to tertiary centers for
primary PTCA may be permissible if the procedure cannot
be done within the first 2 hours of symptom onset. Clearly,
it becomes critical to measure the outcomes of larger
numbers of patients stratified by time to answer this
important question. On the other hand, if a time-dependent
worsening of mortality does exist for patients undergoing
angioplasty (as seems likely since it does so for patients
reperfused with fibrinolytic therapy), it seems reasonable to
explore the theoretical advantage of combining the admin-
istration of smaller doses of fibrinolytic agents on presenta-
tion at the community hospital (for early patency) with
prompt transfer to a tertiary center for percutaneous coro-
nary intervention (PCI) (sustained patency). The safety of
such an approach has been reported by Dr. Allan Ross for the
PACT Trial at the 71st Scientific Sessions of the American
Heart Association, in Dallas, Texas, on November 10, 1998.
Until more data have more reliably quantified a benefit of
primary PTCA over thrombolytic therapy in the commu-
nity setting, it seems prudent to suggest that institutions
that do not have the capability of offering primary PTCA
should not feel compelled to develop such services at this
time (121,807).
Text added to “Primary PTCA,” page 1351, column 2:
new paragraph added before “Recommendations for Early
Coronary Angiography . . .”
The most recent developments in acute reperfusion by
mechanical interventions in the management of patients
with AMI are the emerging reports of randomized compar-
isons between primary PTCA and routine deployment of
stents (127,808). The Amsterdam group (127) published a
randomized comparison of coronary stenting with balloon
angioplasty in selected patients with AMI that showed that
primary stenting can be used safely and effectively, resulting
in a lower incidence of recurrent infarction and a significant
reduction in the need for subsequent target-vessel revascu-
larization compared with balloon angioplasty. These data
support the concept that with improved stent technique and
use of more effective antiplatelet regimens, including ticlo-
pidine, the thrombus-laden lesion no longer represents a
strict contraindication to stenting. An appropriate note of
caution has been made about interpreting these data (809),
pointing out the highly selective nature of the study popu-
lation. Only 50% of patients with AMI who underwent
primary PTCA were considered eligible for this study,
raising serious questions about the generalizability of the
results.
The STENT PAMI (Stents–Primary Angioplast in
Acute MI) Trial reported the results of randomly assigning
900 AMI patients to PTCA or PTCA with deployment of
a heparin-coated stent at the 71st Scientific Sessions of the
American Heart Association held in Dallas in November
1998. The primary end point was the incidence of the
combination of death, reinfarction, disabling stroke, or
ischemic-driven, target-vessel revascularization at 6 months.
Although there was a statistically significant difference in
the combined end point that favored stent placement
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compared with PTCA alone (12.4% versus 20.1%, P ,
0.01), this was determined solely by the incidence of
target-vessel revascularization at 6 months (7.5% versus
17%, P , 0.0001, respectively). Unfortunately, there were
more deaths in the stent placement arm (4.2%) than in the
PTCA arm (2.7%), although the difference was not statis-
tically significant in this trial, which had a total of only 31
deaths.
Text added to “Patient Characteristics,” page 1352, column
1: new text replaces paragraphs beginning “Ischemic-type
chest discomfort . . .” through “The early descriptions of
MI . . .”
In the setting of nondiagnostic ECG findings (non-ST
elevation), ACS represents a continuum between chronic
stable angina and AMI with ST-segment elevation. Al-
though the prognosis of the patient with chronic stable
angina can be stratified and the emergency situation engen-
dered by ST-elevation MI is readily evident, patients with
acute symptoms but nondiagnostic ECG findings range
from those with noncardiac chest pain to very high-risk MI
with multivessel disease. Unstable angina and MI without
ST elevation represent 2 of the most common cardiac
emergencies requiring hospitalization and account for
.650,000 discharges per year in the United States. Al-
though the optimal treatment regimen or strategies for such
patients is under investigation, a proposed diagnostic
schema is presented in Figure 2 and a therapeutic approach
is depicted in revised Figure 4.
AMI accompanied by nondiagnostic ECG changes is
believed to be related to acute disruption of an atheroscle-
rotic plaque in the setting of chronic inflammatory infiltra-
tion of its fibrous cap; this underlying pathophysiology is
not thought to differ from AMI accompanied by ST-
segment elevation. As more angiographic and clinical cor-
relation studies are done, it is becoming clear that total
occlusion of the culprit vessel is much less common in AMI
without ST-segment elevation than in MI with ST eleva-
tion (82,138–140). Furthermore, patients without ST-
segment elevation are more likely to have multivessel disease
and prior MIs than are those with ST-elevation MI (810).
In the clinical history, patients with MI without ST-
segment elevation are more likely than those with ST
elevation to have a history of diabetes, hypertension, heart
failure, and peripheral vascular disease but less likely to be
smokers or to have hyperlipidemia (810). Importantly, the
elderly are less likely to have ST-segment elevation with
MI, probably because of the more common presence of
prior myocardial damage and multivessel disease (25,149).
Thus, during initial evaluation of the patient with acute
ischemic-type chest discomfort, the clinician should classify
patients as those with ST elevation or LBBB (acute reper-
fusion indicated) and those with nondiagnostic ECGs. The
nondiagnostic ECG group will include patients with non-
cardiac symptoms, those with unstable angina and no
myocardial necrosis, those with small MIs, those with direct
posterior infarctions caused by circumflex artery occlu-
sion, and those at very high risk with multivessel coronary
disease and significant left ventricular dysfunction. Stud-
ies with different mixes of these subgroups have reported
different morbidity and mortality rates for the population
as a whole.
Figure 4. All patients without ST elevation should be treated with
an antithrombin and aspirin (ASA). Nitrates should be adminis-
tered for recurrent episodes of angina. Adequate b-adrenoceptor
blockade should then be established; when this is not possible or
contraindications exist, a calcium antagonist can be considered.
Current data indicate that either an invasive or noninvasive
treatment strategy is suitable for non–ST-elevation AMI patients.
AMI 5 acute myocardial infarction, CABG 5 coronary artery
bypass graft; ECG 5 electrocardiographic, GpIIb/IIIa 5 glyco-
protein IIb/IIIa receptor for platelet aggregation, LMWH 5
low-molecular-weight heparin, LV 5 left ventricular, PTCA 5
percutaneous transluminal coronary angioplasty.
Modified from Antman EM. Medical therapy for acute coro-
nary syndromes: an overview. In: Califf RM, editor. Atlas of Heart
Diseases, VIII. Philadelphia: Current Medicine; 1996.
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The initial importance of classifying patients on the basis
of the ECG should not be confused with the question of
whether the patient has a Q-wave or a non–Q-wave MI.
This classification can be made only after 24 hours, well
beyond the point at which critical decisions about treatment
must be made. Whether or not the patient initially has ST
elevation, those with a normal QRS complex who do not
develop Q waves with MI have a low in-hospital mortality
rate, but recurrent ischemia, recurrent MI, and death in the
weeks after discharge occur frequently. In contrast, patients
with a significant QRS abnormality who do not develop
new Q waves with a new MI are at high risk of both early
and later death. The overall incidence of non–Q-wave MI
may be increasing with the advancing age of the population
and the greater use of thrombolytic therapy, aspirin, and
b-adrenoreceptor blockers.
New section, page 1353, column 2: new text added before
“Interventional Therapy”
Antithrombotic therapy. Thousands of patients with ACS
without ST-segment elevation have now been randomly
assigned to treatment with various antithrombotic regimens.
In these trials, approximately half the patients had enzymes
positive for myocardial necrosis on the first measurement,
indicating that they were having an MI without ST-
segment elevation at the time of randomization. Patients
with positive enzymes on the first draw not only had a
higher mortality rate than patients without positive enzymes,
but they also had a higher risk of repeat MI, hemodynamic
complications, and arrhythmias. Fortunately, the response to
newer antithrombotic agents has been homogeneous in pa-
tients with ACS without ST elevation, whether or not they
had positive enzymes at the time of admission.
New section, page 1353, column 2: new text added before
“Interventional Therapy.” Follows “Antithrombotic Therapy.”
Glycoprotein IIb/IIIa inhibitors. The GP IIb/IIIa recep-
tor is a member of the integrin family of receptors that is
found in the membrane of platelets (811). When platelets
are activated by a variety of stimuli, including thrombin,
collagen, adenosine diphosphate (ADP), and epinephrine,
the GP IIb/IIIa receptor changes conformation to be
receptive to one end of a fibrinogen dimer. Occupancy of a
GP IIb/IIIa receptor by the other end of the dimer provides
the basis for platelet aggregation. Thus, the GP IIb/IIIa
receptor is considered the final common pathway of platelet
aggregation (812). Multiple therapeutic agents have now
been developed to block the receptor.
More than 30,000 patients with ACS without ST-
segment elevation have now been randomly assigned into
trials comparing GP IIb/IIIa inhibitors with placebo in addi-
tion to treatment with aspirin and unfractionated heparin
(UFH). A systematic overview has demonstrated a definite
reduction in the composite end point of death and MI and in
the composite end point of death, MI, and the need for
revascularization procedures (813). A slight trend toward a
reduction in mortality may exist but does not reach statistical
significance. The reduction in events is present while patients
are treated with active drug, and the difference in event rates
does not change after that point. When treatment is discon-
tinued, no further effect, either beneficial or detrimental, is
seen. Thus, intravenous GP IIb/IIIa inhibitors may be consid-
ered as a method to reduce acute events and stabilize patients
in the acute phase of MI without ST-segment elevation.
Direct comparisons of the agents are not available, so the
specific choice of which agent to use is speculative.
Three agents are available for clinical practice:
1. Abciximab is a chimeric Fab fragment of a monoclonal
antibody to the GP IIb/IIIa receptor. Although multiple
clinical trials have documented the reduction in the
composite of death and nonfatal MI with abciximab in
the setting of percutaneous intervention (814–817), only
1 trial (Chimeric 7E3 Antiplatelet in Unstable Angina
Refractory to Standard Treatment [CAPTURE]) (814)
has been completed in the setting of non–ST-elevation
ACS.
2. Eptifibatide is a cyclical heptapeptide, which binds to the
receptor with a short half-life (818). It has been evalu-
ated in a trial of 11,000 patients with non–ST-elevation
ACS, 45% of whom had enzymes positive for myocardial
necrosis on admission.
3. Tirofiban is a small nonpeptide compound that also has
a short half-life. It has been evaluated in 5147 patients in 2
randomized trials of non–ST-elevation ACS (819,820). In
the PRISM-PLUS Study (Platelet Receptor Inhibition in
Ischemic Syndrome Management in Patients Limited by
Unstable Signs and Symptoms) (820), 45% of patients also
had positive enzymes for myocardial necrosis.
New section, page 1353, column 2: new text added to end
of paragraph 1, before “Interventional Therapy”
Low-molecular-weight heparin and direct antithrom-
bins. Low-molecular-weight heparin (LMWH) is a sub-
fraction of standard heparin with a greater degree of
inhibition of factor Xa relative to thrombin when compared
with standard UFH. In addition to its convenience—it can
be administered subcutaneously with high bioavailability—
LMWH has a number of theoretical benefits over UFH.
These include the potential to prevent thrombin generation
as well as inhibit thrombin, the lack of a need to monitor
with coagulation testing, and a lower rate of heparin-
associated thrombocytopenia. Four trials have compared the
use of LMWH and UFH for non–ST-elevation ACS
(507,838–840). In 2 trials, a clear benefit of LMWH was
observed (839,840), whereas in another, LMWH was su-
perior to placebo (507). The fourth trial did not show a clear
difference in outcomes (838).
Direct-thrombin inhibitors are now available for use in
heparin-induced thrombocytopenia and deep venous
thrombosis, but they have not been approved for treatment
of ACS. Hirudin, a recombinant protein that is an impor-
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tant component of leech saliva, has been studied in many
thousands of patients; the results show a consistent reduc-
tion in the composite of death and nonfatal MI. Hirulog, a
synthetic direct thrombin inhibitor, has been studied in only
limited populations.
Text added to “Interventional Therapy,” page 1353,
column 2, new paragraph added before paragraph
beginning “There is considerable variation . . .”
Recently, the Veterans Affairs Non–Q-Wave Infarction
Strategies In Hospital Trial (VANQWISH) (821) has shed
important light on the question of intervention in patients
with non–Q-wave infarction. The VANQWISH Trial
evaluated a somewhat different population than the
Thrombolysis in Myocardial Infarction (TIMI-3B) Trial.
VANQWISH investigators randomly assigned to an inva-
sive or conservative strategy 920 patients who did not have
a major complication within 24 to 72 hours of onset of
symptoms. The ECG criteria required the absence of new
Q waves; therefore, the trial included patients with and
without ST-segment elevation on admission. The aggres-
sive strategy called for routine cardiac catheterization with
revascularization of significant lesions, whereas the conser-
vative strategy used intensive medical therapy; angioplasty
was used only in patients with recurrent ischemia or
hemodynamic compromise. In this trial of management of
non–Q-wave MI, there was a 28% rate of cardiac events
during follow-up of 12 to 44 months but no early or late
clinical benefit with routine invasive management. There
was no difference in the primary end point of combined
death or nonfatal MI during the average follow-up of 23
months (138 patients assigned to the invasive strategy versus
123 patients assigned to the conservative strategy, P 5
0.35). There was a significantly higher rate of death among
patients assigned to invasive treatment both at hospital
discharge (21 versus 6, P 5 0.007) and at 1 year (58 versus
36, P 5 0.025). Concern has been raised about the operative
mortality rate observed in the trial (7.7% for the composite
group and 11.6% for those assigned to the invasive strategy);
however, it has been demonstrated that the centers enrolling
patients in the trial had operative mortality rates within the
expected range for all centers in the United States.
Although the TIMI-3B and VANQWISH trials did not
involve identical populations, both studies failed to support
the notion that an aggressive approach to revascularization
in non–ST-segment elevation ACS reduces the risk of
death or nonfatal MI. A contrary view was expressed in the
preliminary report of the Fragmin During Instability in
Coronary Artery Disease (FRISC) Trial II presented on
March 7, 1999, at the 48th Scientific Sessions of the
American College of Cardiology, in New Orleans, Louisi-
ana. The FRISC report indicated that, when combined with
an early invasive strategy, the LMWH dalteparin may
reduce early events in patients with unstable coronary artery
disease. In the open acute phase of the trial, 2267 patients
with unstable angina or non–Q-wave MI received daltepa-
rin, 120 IU/kg every 12 hours during the first 5 to 7 days. In
the subsequent double-blind phase, 2015 of these patients
were randomly assigned to receive subcutaneous dalteparin
5000 to 7500 IU/kg twice daily or placebo for 3 months.
Results at 90 days showed no significant difference
between the dalteparin and placebo groups in terms of the
primary end point (death or MI); however, during the first
45 days, there was a significant reduction in the primary end
point among those receiving dalteparin compared with
those receiving placebo (3.7% versus 6.5%, respectively; P 5
0.003). During the prolonged treatment phase, the inci-
dence of bleeding events was 26% with dalteparin and 10%
with placebo. In addition to being randomly assigned to
receive dalteparin or placebo, patients enrolled in FRISC II
were assigned within 48 hours to invasive or noninvasive
early management. The invasive strategy consisted of early
coronary angiography (within 2 to 7 days), whereas the
noninvasive strategy consisted of exercise testing with refer-
ral to coronary angiography if the test was positive or further
events warranted it. At 6 months the rate of death or MI in
the invasive group was 9.5% versus 12% in a noninvasive
group (P 5 0.045). According to subgroup analyses, men
particularly benefited from an early invasive strategy, with
the rate of death or MI among invasive versus noninvasive
groups at 9.1% versus 13.9%; P 5 0.002.
It will be interesting to learn whether other antithrom-
botic/antiplatelet therapies will produce an environment in
which medical therapy alone will be sufficient or whether it
will foster improved results with aggressive interventions,
which is being addressed in ongoing clinical trials (822).
New section, page 1354, column 1: new text added before
“Hospital Management”
Glucose-insulin-potassium infusion. Metabolic modula-
tion of AMI patients, originally proposed by Sodi-Pallares
(823) in 1962, was recently evaluated in a pilot trial by the
Estudios Cardiologicos Latinoamerica (ECLA) Collabora-
tive Group (824) in South America. In this recently re-
ported study, 407 patients admitted within 24 hours of
onset of symptoms of a suspected MI, regardless of age or
ECG findings, were randomly assigned to either a high-
dose infusion of glucose-insulin-potassium (GIK) (25%
glucose, 50 IU/L soluble insulin, and 80 mmol/L KCl at a
rate of 1.5 mLzkg21zh21 for 24 hours) or a low-dose
infusion (10% glucose, 20 IU/L soluble insulin, and 50
mmol/L KCl at a rate of 1 mLzkg21zh21 for 24 hours) or
usual care. A significant reduction in the composite end
point of death, nonfatal severe heart failure (greater than
Killip class 2), and nonfatal ventricular fibrillation was
observed for the overall study population as well as the 252
patients (62%) who also were treated with reperfusion
strategies. This latter group also showed a statistically
significant reduction in mortality rate (relative risk [RR],
0.34; CI, 0.78 to 10.1, 2 P 5 0.008). A strong relationship
was also found between the time from symptom onset and
impact of infusion. A significant reduction in mortality rate
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was observed in patients treated #12 hours after symptom
onset (RR, 0.43; 95% CI, 0.2 to 0.9; P 5 0.021). Because
these results show that a metabolic modulating strategy is
feasible in the early hours of an AMI with a GIK infusion
in contemporary practice, it is hoped that an appropriately
sized clinical trial will get under way soon. The results may
have strong implications for incorporating this rather simple
and inexpensive therapy for the routine care of AMI
patients worldwide.
New text added to “Triage of Patients With Acute
Myocardial Infarction and Other Coronary Syndromes,”
page 1357, column 2: new paragraph added after line 37,
“. . . and treatment success.”
Two large studies have been published that support these
concerns (210,825). A survey of 7560 nurses from across the
United States suggests that nurses are caring for increasing
numbers of patients and are required to cross-train for more
responsibilities; 74% report having less time to teach pa-
tients and families, and 69% report less time to provide basic
nursing care. Forty-nine percent reported that registered
nurses working on a part-time or temporary basis have
replaced full-time staff, and 36% reported an increase in
nonlicensed assistive personnel. Staffing and perceived qual-
ity of care were significantly lower in the Pacific and
northeastern regions of the country, where managed care is
prevalent (210).
Objective data on quality outcomes were obtained from
the American Nurses’ Association (825) from a recent study
of 502 hospitals in California, Massachusetts, and New
York. These data demonstrated that adverse outcomes (ie,
pressure ulcers, pneumonia [not community acquired],
urinary-tract infections, and postoperative infections) and
hospital lengths of stay were associated with RN staffing
levels. Adverse events were higher in institutions with lower
RN staffing levels. As RN staffing levels decreased, patient
length of stay increased, presumably because of adverse
events.
A recent report on the adequacy of staffing from the
Institute of Medicine (826) concluded that there was
sufficient evidence from several studies using different types
of quality measures to conclude that there is a positive
relationship between nursing-staff levels and the quality of
care in nursing homes. The evidence is not sufficient,
however, to conclude that such a relationship exists in
hospitals. It has been suggested that patient variables (eg,
severity of illness) contribute significantly to the variance in
outcome and that adverse events may be a more sensitive
marker of differences in organizational quality (ie, collabo-
ration, leadership, organizational culture, job satisfaction)
than staffing ratios (827,828). Taken together, the research
in this area suggests that adverse events are not simply the
result of changes in staffing levels but more a function of
fundamental changes in institutions as a result of reorgani-
zation and restructuring. If so, quality-monitoring activities
in hospitals will be essential as the current trend in managed
care penetrates the rest of the country.
Text added to “Management of Mechanical Defects After
AMI,” page 1370, column 2: new text replaces first 2
sentences of paragraph beginning “Coronary angiography
can . . .”
Coronary arteriography can delineate the presence of surgi-
cally correctable coronary artery disease, and cardiac cathe-
terization may better delineate the presence of a mechanical
defect if other studies are not clear. However, the evidence
for concomitant CABG associated with surgical repair of an
acute ventricular septal defect (VSD) is inconclusive (829).
Although there is a need to minimize invasive angiographic
procedures before early surgical correction of the ruptured
septum, initial coronary arteriography to assess the coronary
anatomy seems warranted in most cases.
Text added to “Postinfarction Ventricular Septal Defect,”
page 1371, column 1: new text replaces paragraph
Increased frequency of acute rupture of the interventricular
septum (VSD) as well as earlier presentation may be noted
in patients who have undergone thrombolytic therapy (383).
Although emergency surgical repair was formerly thought to
be necessary only in patients with pulmonary edema or
cardiogenic shock, it is now recognized as equally important
in hemodynamically stable patients (384,385,830). Because
all septal perforations are exposed to sheer forces and
necrotic tissue removal processes by macrophages, the rup-
ture site can abruptly expand, resulting in sudden hemody-
namic collapse even in patients who appear to be clinically
stable with normal left ventricular function (830). For this
reason, prompt insertion of an intra-aortic balloon pump
and referral for emergency operation are recommended for
every patient with acute VSD as soon as the septal rupture
is diagnosed. Simultaneous CABG, if feasible, seems war-
ranted in patients with extensive coronary artery disease
(386).
Section renamed and text added, page 1374, column 2:
new text added as a second paragraph under new head
TICLOPIDINE AND CLOPIDOGREL
In 1 trial, ticlopidine has been shown to be more effective
than placebo (no aspirin) in reducing the occurrence of
vascular death or MI at 6 months in patients with unstable
angina (441). Of note, there was no difference in the
number of events over the first 7 to 10 days, a finding
consistent with the delayed onset of the antiplatelet effect.
Ticlopidine has been approved for clinical use in patients
with cerebral ischemia when aspirin has failed, cannot be
tolerated, or is contraindicated. However, 2 serious side
effects associated with its use have been observed: Reversible
neutropenia has been observed when treatment continues
for .2 weeks. Ticlopidine can also cause thrombotic throm-
bocytopenic purpura (TTP). Several cases of TTP have
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been reported, and in a review of 60 cases, 20% occurred
after only 3 to 4 weeks of therapy, but only 3% of patients
treated for #14 days developed TTP. Furthermore, mor-
tality is high: ’50% of untreated cases and 25% of treated
cases (830a).
Ticlopidine and clopidogrel are ADP-receptor antago-
nists and quite similar chemically. However, TTP has not
been reported with use of clopidogrel, and in the large
CAPRIE Trial (Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events) (831), the incidence of a signifi-
cant reduction in neutrophils was only 0.10% in the clopi-
dogrel group and actually slightly higher, at 0.17%, in the
aspirin group. In that trial, there was a statistically signifi-
cant relative risk reduction in vascular death, MI, or stroke
of 8.7% in favor of clopidogrel. For these reasons, in many
catheterization laboratories, ticlopidine has been replaced
with clopidogrel combined with aspirin for the prevention
of adverse cardiac events after stent implantation. The
effectiveness of this regimen, however, is unknown. Clopi-
dogrel is also preferable to ticlopidine for patients who
demonstrate aspirin resistance or for whom aspirin is con-
traindicated because of hypersensitivity.
Text added to “Thrombolytic Agents: General Mechanisms
of Action and Pharmacological Properties,” page 1375,
column 2: text added between paragraph ending
“. . . center of plasmin,” and paragraph beginning “Aside
from this . . .”
Aside from this similarity, some comparative features of the
Food and Drug Administration–approved thrombolytic
agents for intravenous therapy (streptokinase, anistreplase,
alteplase, and reteplase) are presented in the revised Table 8.
Streptokinase and urokinase are approved for intracoronary
use, but this route of administration for AMI is now
virtually obsolete. In addition, newer agents have been
developed (eg, TNK-tissue plasminogen activator [TNK-
tPA] and lanetoplase). Recent trials with alteplase have used
an accelerated regimen given over 90 minutes. The accel-
erated regimen leads to the highest patency rate without an
increase in ICH and has become the preferred method of
administration. The advantage of reteplase is that it can be
given by bolus, which is convenient. A recent trial compared
the effectiveness and safety of continuous infusion versus
double-bolus administration of alteplase (832). The trial
was stopped prematurely because of concern about the safety
of the double-bolus injection. The rate of hemorrhagic
stroke was 1.12% after double-bolus injection of alteplase
compared with 0.81% after accelerated infusion of alteplase.
Text added to “Comparative Thrombolytic Efficacy,” page
1376, column 2: new paragraph added before
“Considerations in Selecting Thrombolytic Regimens”
Since the initial publication of these guidelines, the Food
and Drug Administration has approved the fibrinolytic
agent reteplase for use. Reteplase, a mutant of wild-type
tPA, has a longer half-life than its parent molecule and has
been compared with alteplase in a large clinical trial (833).
An angiographic trial (834) found that 60- and 90-minute
TIMI grade 3 flow and coronary patency rates were higher
with reteplase than with the accelerated dose of alteplase.
When compared with an accelerated infusion of alteplase,
reteplase did not provide any additional survival benefit.
The mortality rate at 30 days was 7.5% for reteplase and
7.2% for alteplase; and the rates of the combined end point,
death or nonfatal MI–disabling stroke, were 7.98% and
7.91%, respectively.
Text added to “Considerations in Selecting Thrombolytic
Regimens,” page 1376, column 2: text added as first
paragraph
GUSTO-I (228), GUSTO-III (833), and other recent
studies (467,468) suggest that accelerated alteplase and
reteplase with intravenous heparin are currently the most
effective therapies for achieving early coronary reperfusion,
but both are substantially more expensive and carry a slightly
greater risk of ICH than streptokinase. Thus, the cost-
benefit ratio is greatest in patients presenting early after
onset of chest pain or symptoms and in those with a large
Replacement Table 8. Comparison of Approved Thrombolytic Agents
Streptokinase Anistreplase Alteplase Reteplase
Dose 1.5 MU in 30–60 min 30 mg in 5 min 100 mg in 90 min 10 U 3 2 over 30 min
Bolus administration No Yes No Yes
Antigenic Yes Yes No No
Allergic reactions
(hypotension most common)
Yes Yes No No
Systemic fibrinogen depletion Marked Marked Mild Moderate
90-min patency rates (%) ’50 ’65 ’75 ’75
TIMI grade 3 flow (%) 32 43 54 60
Mortality rate in most recent
comparative trials (%)
7.3 10.5 7.2 7.5
Cost per dose (US) $294 $2116 $2196 $2196
TIMI 5 Thrombolysis in Myocardial Infarction.
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area of injury (eg, anterior infarction) and at low risk of
ICH. Other promising thrombolytic agents under investi-
gation are TNK-tPA and lanetoplase, both of which are
mutant forms of wild-type tPA and can be given as a single
bolus.
Two equivalence trials comparing these agents with the
accelerated infusion of alteplase reported preliminary results
in March 1999 at the 48th Scientific Sessions of the
American College of Cardiology.
Data from the In TIME-II Study showed the single-
bolus thrombolytic lanetoplase (nPA) was as effective in
reducing the 30-day mortality rate as tPA in patients with
AMI. The trial randomly assigned 15,078 patients within 6
hours of symptom onset to receive single-bolus lanetoplase
(120,000 U/kg) or front-loaded alteplase (up to 100 mg).
The 30-day mortality rate (primary end point) in the nPA
and tPA groups was 6.7% and 6.6%, respectively. At 24
hours, mortality was slightly lower with nPA than with tPA
(2.39% versus 2.49%). The nPA group had a significantly
higher incidence of ICH than the tPA group (1.13% versus
0.62%; P 5 0.003).
The ASSENT-2 trial reported preliminary results from
TNK-tPA, the other novel thrombolytic agent delivered by
single bolus (790). Within 6 hours of symptom onset,
16,950 patients with AMI were randomly assigned to
weight-adjusted TNK-tPA or accelerated tPA. The 30-day
mortality rate was 6.17% in the TNK-tPA group and 6.18%
in the accelerated tPA group. The incidence of total stroke
was similar (1.78% versus 1.66%) as was hemorrhagic stroke
(0.93% versus 0.94%), and mild to moderate bleeding was
observed less often in the TNK-tPA group than in the tPA
group (26% versus 28.1%; P , 0.002). Although the efficacy
of these agents appears to be equivalent to tPA, it will be
important to carefully assess the adverse event rates when
these studies are published.
There is considerable ongoing investigation of the effec-
tiveness of thrombolytic therapy alone compared with the
combination of either direct-acting antithrombins or the
GP IIb/IIIa receptor antagonists as a means to improve
effectiveness over the currently available regimen. In 2
studies that evaluated the combination of hirudin (desiru-
din) with alteplase and streptokinase, there was no im-
provement in mortality rate, and the therapeutic-to-severe
bleeding profile appeared to be very close (TIMI-9 and
GUSTO-IIb trials).
Over the past few years, there has been an increase in the
number of patients who undergo primary angioplasty for
treatment of AMI in hospitals with tertiary cardiac facilities.
This has been driven to a large extent by the observed higher
patency in TIMI-3 flow rates associated with coronary
angioplasty as well as the desire of cardiologists to assess
coronary anatomy and ventricular function early in patient
management. Still, however, this represents only a small
portion of patients with AMI, and thrombolytic therapy
remains the major means of reperfusion.
New text added to “Current Use Rates for Thombolytic
Therapy,” page 1377, column 1: new text replaces
paragraph 1
The industry-sponsored NRMI tracks the use of thrombo-
lytic therapy in the United States and has enrolled 330,928
patients treated at 1470 US hospitals during its second
phase (NRMI-2) from June 1994 through July 1996. Barron
et al (789) recently reported an analysis of this database,
attempting to determine what proportion of patients with
an MI who are eligible for reperfusion therapy do not
receive this proven treatment. Barron used a conservative
definition of thrombolytic eligibility (diagnostic changes on
ECG or LBBB #6 hours after onset of symptoms and no
contraindication to thrombolytic therapy indicated); inves-
tigators found that 31% of their cohort were eligible for
reperfusion therapy; 25% had nondiagnostic initial ECGs;
41% presented .6 hours from onset of symptoms, and 3%
had contraindications to thrombolytic therapy.
Of those who were eligible for thrombolytic therapy, 24%
did not receive any form of reperfusion therapy (7.5% of all
patients). Multivariate analysis revealed that the indepen-
dent predictors for eligible patients not being given reper-
fusion therapy were the presence of LBBB, the disappear-
ance of chest pain at the time of presentation, age .75
years, female gender, and various preexisting cardiovascular
conditions. Perhaps most disconcerting was the finding that
patients with the highest risk of death from AMI were the
least likely to receive reperfusion therapy (eg, patients with
a history of congestive heart failure or the presence of
LBBB). Both groups had an in-hospital mortality rate of
’20%, well above the mortality rate of 7.9%, yet the
presence of LBBB made it 78% less likely that a patient
would receive reperfusion therapy than patients who pre-
sented with ST-segment elevation.
New section, page 1380, column 1: new text added before
paragraph beginning “Newer direct antithrombin . . .”
Low-molecular-weight heparins. LMWH preparations
are formed by controlled enzymatic or chemical
depolymerization-producing saccharide chains of varying
length but with a mean molecular weight of ’5000 (835).
A critical chain length of 18 saccharides is required to form
the ternary complex consisting of a heparin fragment,
antithrombin, and thrombin. In addition to the critical
pentasaccharide sequence discussed above and required for
attachment of a heparin fragment to antithrombin, an
additional 13 saccharide residues are necessary to allow the
heparin fragment to simultaneously attach to the heparin-
binding domain of thrombin and create the ternary complex
(836). Creation of short-chain or LMWH fragments ,18
saccharides in length retain the critical pentasaccharide
sequence but are of insufficient length to permit attachment
to the heparin-binding domain of thrombin, and therefore
thrombin is not inhibited by such short-chain fragments.
However, only the critical pentasaccharide sequence is
900 Ryan et al. JACC Vol. 34, No. 3, 1999
1999 Update: Management of AMI September 1999:890–911
required for binding to antithrombin and inhibition of
factor Xa. Thus, through the creation of a mixture of short-
and long-chain heparin fragments, preparations of varying
antiXa:antiIIa activity may be developed. Additional fea-
tures of LMWHs of particular clinical relevance are a
decreased sensitivity to platelet factor IV, a more stable,
reliable anticoagulant effect, and lower rates of thrombocy-
topenia and heparin-induced thrombocytopenia syndrome.
Thus, LMWHs are clinically attractive because of better
bioavailability, ease of administration via the subcutaneous
route, and enriched anti-Xa activity (837). Higher anti-Xa
activity is important because of the multiplier effect in which
1 molecule of factor Xa leads to production of many
molecules of thrombin.
Gurfinkel and colleagues (507) compared placebo treat-
ment, UFH, and the LMWH nadroparin in 219 patients
with unstable angina who were also treated with aspirin.
Combination therapy with aspirin plus nadroparin signifi-
cantly reduced the number of patients with an adverse end
point event (combined death, MI, and recurrent angina)
during the study period, from 59% in the aspirin group and
63% in the aspirin-plus-heparin group to 22% in the
aspirin-plus-nadroparin group (P , 0.0001 for comparisons
of the nadroparin group with each of the other 2 groups).
The FRISC Trial (506) was designed to determine
whether subcutaneous administration of the LMWH dalte-
parin (Fragmin) would reduce ischemic events during the
acute in-hospital period after an episode of unstable angina/
non–Q-wave MI. A secondary goal was to determine
whether long-term anticoagulation therapy would provide
additional benefit compared with anticoagulation restricted
only to the acute phase (the first few days after hospitaliza-
tion) of an acute coronary syndrome. Patients presenting
#72 hours after onset of unstable angina/non–Q-wave MI
were randomly assigned to receive either dalteparin
(120 IU/kg subcutaneously twice daily for 6 days followed
by daily subcutaneous injections of 7500 IU for an addi-
tional 35 to 45 days; n 5 746) or placebo (n 5 760). All
patients received aspirin. Compared with the placebo group,
dalteparin-treated patients experienced a 63% reduction in
death and nonfatal MI at the 6-day evaluation (4.8% in the
placebo group compared with 1.8% in the dalteparin group,
P 5 0.001). However, with longer-term follow-up, event
rates for the 2 groups began to converge, and a nonsignif-
icant trend toward improved outcome was observed in the
dalteparin group (10.7% event rate for the placebo group,
compared with 8.0% with dalteparin; RR, 0.75; P 5 0.07)
by 40 days. By 150 days, there was no significant difference
between the 2 groups.
The Fragmin in Unstable Coronary Heart Disease
(FRIC) Study (838) compared dalteparin with IV heparin
in patients with unstable angina/non–Q-wave MI present-
ing #72 hours after an episode of ischemic chest pain.
During the acute phase (the first 6 days after hospitaliza-
tion), patients received either subcutaneous dalteparin twice
daily or UFH infused intravenously during the first 48
hours; during the chronic phase, subcutaneous dalteparin or
placebo was continued until day 45. All patients received
aspirin throughout the course of the study. The occurrence
of the composite outcome of death, MI, or recurrent angina
was similar for the UFH and dalteparin groups during the
6-day acute period (7.6% versus 9.3% for the UFH and
dalteparin groups, respectively). Similarly, after 45 days, the
incidence of death, MI, or recurrent angina was 12.3% for
both groups.
The Efficacy and Safety of Subcutaneous Enoxaparin in
Non–Q-Wave Coronary Events (ESSENCE) Study (839)
examined the effectiveness of enoxaparin in unstable angina/
non–Q-wave MI. In this large, multicenter, double-blind
trial, 3171 patients were randomly assigned to receive either
twice-daily subcutaneous injections of enoxaparin (1 mg/kg)
or continuous intravenous infusion of UFH during the acute
period (2 to 8 days) after hospitalization for unstable
angina/non–Q-wave MI. The primary end point was a
composite of death, MI, or recurrent angina #14 days after
hospitalization. The median duration of treatment with the
study drug was 2.6 days. The rate of end point events was
significantly reduced in the enoxaparin group compared
with UFH (16.6% versus 19.8% for the enoxaparin and
UFH groups, respectively; P 5 0.019). The enoxaparin
group continued to have fewer events than the UFH group
through 30 days, at which time a primary end point event
had occurred in 19.8% of the enoxaparin group and 23.3%
of the UFH group (P 5 0.016). Patients treated with
enoxaparin were also significantly less likely to require
revascularization procedures within 30 days (27.0% versus
32.2%; P 5 0.001). A cost-effectiveness analysis showed
that despite a small increase in drug cost ($75 per patient),
the lower rate of cardiac catheterization and revasculariza-
tion procedures led to a savings of $1172 per patient if
enoxaparin was used instead of UFH.
Although LMWHs share many pharmacological similar-
ities, they also vary in important respects, and it is important
to consider each drug individually rather than as members of
a class of interchangeable compounds. The varying effec-
tiveness of these drugs in clinical trials may reflect differing
anti-Xa:anti-IIa ratios (835). For example, nadroparin and
enoxaparin, both of which have been shown to reduce
ischemic events after unstable angina or unstable angina/
non–Q-wave MI, have in vitro anti-Xa:anti-IIa ratios be-
tween 3 and 4; dalteparin, which appeared to be less
effective, has an anti-Xa:anti-IIa ratio of ’2.2. It is not clear
to what extent these pharmacological parameters influence
the clinical usefulness of the various LMWHs. However, it
is also possible that the lack of sustained effect of LMWH
in the FRISC and FRIC trials was due to the long
patient-enrollment period after the last episode of qualifying
chest pain (72 hours in both studies), in contrast to a
24-hour enrollment period used in most other studies.
TIMI-11A (840) was a dose-finding study to assess the
safety and tolerability of 2 enoxaparin doses in patients with
unstable angina/non–Q-wave MI. The incidence of major
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hemorrhage was 6.5% in patients who received 1.25 mg/kg
enoxaparin subcutaneously every 12 hours for 2 to 8 days but
decreased to 1.9% in patients receiving 1.0 mg/kg every 12
hours.
TIMI-11B enrolled 4020 patients with unstable angina/
non–Q-wave MI to compare 2 strategies of antithrombotic
therapy: UFH during the acute phase followed by placebo
subcutaneous injections during the chronic phase versus
uninterrupted therapy with subcutaneous enoxaparin during
both the acute and chronic phases (840a). The primary
efficacy end point is the occurrence through day 43 of the
sum of death/nonfatal MI not present at enrollment or
severe recurrent ischemia requiring urgent revascularization.
The primary safety end point is the development of major
hemorrhage or serious adverse event(s) related to study
drug.
Kaplan-Meier curves of the primary end point showed a
lower rate of events beginning 8 hours after randomization
in the enoxaparin-treated patients. At 48 hours there was a
statistically significant 24% relative risk reduction from 7.3%
in the UFH group to 5.5% in the enoxaparin group. The
superiority of enoxaparin was seen in both patients who
were treated with UFH and were outside the target aPTT
range and patients who were in the target aPTT range. By
14 days, the rate of death/MI/urgent revascularization was
16.7% in the UFH group and 14.2% in the enoxaparin
group, a relative risk reduction of 15% (P 5 0.03). All
individual elements of the composite end point were re-
duced in the enoxaparin group.
After treatment in the acute phase, eligible patients
entered the long-term phase. Kaplan-Meier curves contin-
ued through day 43 showed maintenance of the initial
benefit in favor of enoxaparin but no additional relative
decrease in events during long-term treatment with enox-
aparin compared with placebo.
New section, page 1380, column 1: text added before the
paragraph beginning “Newer direct antithrombin . . .”
CONCLUSION
Enoxaparin for the acute management of patients with
unstable angina/non–Q-wave MI has been shown to be
superior to UFH for reducing death and serious cardiac
ischemic events. This superiority is achieved without an
increase in the rate of either spontaneous or instrumented
major hemorrhage. The initial benefit observed with enox-
aparin is sustained through day 43; however, no further
relative decrease in events was observed in the chronic
phase. There was an increase in the rate of major hemor-
rhage (both spontaneous and instrumented) with long-term
enoxaparin treatment.
New section, page 1380, column 1: new text before
paragraph beginning “Newer direct antithrombin . . .”
(text follows new Conclusion)
Low-molecular-weight heparins as an adjunct to throm-
bolysis. Another phase II trial in progress, the Hyperten-
sion Audit of Risk Factor Therapy (HART-II) Trial, is
comparing enoxaparin with UFH as adjunctive antithrom-
bin therapy for patients receiving a front-loaded tPA regi-
men for ST-segment elevation MI. The primary end point
is TIMI-3 flow 90 minutes after initiation of thrombolytic
therapy.
Text added to “Secondary Prevention,” page 1396, column
1: new paragraph added before “These results firmly . . .”
Recently, the results of the large Long-Term Intervention
With Pravastatin in Ischemic Disease (LIPID) Study have
been reported. More than 9000 patients are randomly
assigned to either placebo or 40 mg pravastatin daily. The
trial was carried out in a group of patients with a prior
history of MI or unstable angina. It was stopped prema-
turely because of the efficacy of pravastatin in reducing
major cardiovascular events, including a 24% decrease in
coronary heart disease deaths, a 23% decrease in the total
mortality rate, and a 20% decrease in stroke. Benefit has also
been seen in patients with symptomatic coronary disease
who were treated with fluvastatin. In the Lescol in Severe
Atherosclerosis (LiSA) Study, patients with symptomatic
coronary heart disease and hypercholesterolemia who were
given fluvastatin had 71% fewer cardiac events than those in
the placebo group. These results firmly establish the desir-
ability of lowering atherogenic serum lipid levels among
patients who have recovered from AMI.
Text added to “Smoking Cessation,” page 1397, column 1:
new paragraph added before “Long-Term Use of Aspirin”
A new drug, bupropion, has been shown to help some
smokers quit. Nicotine intake is reinforced by activating the
central nervous system to release norepinephrine, dopamine,
and other neurotransmitters. Bupropion is a weak inhibitor
of the neuronal uptake of neurotransmitters. A study of 615
subjects randomly assigned to take placebo or bupropion
achieved good initial quit rates with treatment augmented
by brief counseling at baseline, weekly during treatment,
and intermittently for up to 1 year (841). Seven weeks of
treatment with bupropion was associated with a quit rate of
28.8% (100 mg), 38.6% (150 mg), and 44.2% (300 mg/d);
19.6% of subjects assigned to placebo quit (P , 0.001). At
1 year, 12.4% of the placebo group and 19.6% (100 mg),
22.9% (150 mg), and 23.1% (300 mg) of the bupropion
group remained abstinent. The drug was well tolerated (37
of 462 [8%] stopped treatment prematurely because of
headache, insomnia, or dry mouth), although insufficiently
powered to detect an incidence of seizures known to occur
with related medications. It reduced the weight gain com-
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mon in smokers who quit. Bupropion appears to be another
option for patients who need to quit smoking after AMI.
New section, page 1398, column 1: new text added before
“Antioxidants”
Quality care alert. Indeed, the data supporting the bene-
ficial effect of the long-term use of b-blocker therapy after
AMI is considered so compelling that the Department of
Clinical Quality Improvement of the American Medical
Association has circulated a document endorsed by the
American College of Cardiology, the American Heart
Association, the American College of Physicians, the
American Academy of Family Physicians, and numerous
other societies. The document provides a synthesis and
consensus for the long-term use of b-blockers after AMI.
An expert review panel acknowledged that the data for use
of b-blockers after non–ST-segment elevated AMI are
limited but generally agreed that the totality of evidence
demonstrates the following: use of b-blockers after AMI 1)
decreases cardiovascular mortality, 2) decreases reinfarc-
tions, and 3) increases the probability of long-term survival
by up to 40%.
Although relative contraindications once may have been
thought to preclude the use of b-blockers in some patients,
new evidence suggests that the benefits of b-blockers in
reducing reinfarctions and mortality may actually outweigh
its risks, even in patients with 1) asthma; 2) insulin-
dependent diabetes mellitus; 3) chronic obstructive pulmo-
nary disease; 4) severe peripheral vascular disease; 5) PR
interval .0.24 second; and 6) moderate left ventricular
failure. It is also emphasized that the use of b-blockers in
such patients requires careful monitoring of the patient to be
certain that adverse events do not occur (842–849).
Text added to “Estrogen Replacement Therapy and
Myocardial Infarction,” page 1399, column 2: new text
replaces paragraphs beginning “In 1993 the American
Heart Association . . .” through “Given the overall . . .”
The first large-scale, randomized, double-blind, placebo-
controlled trial that addresses the question of estrogen plus
progestin for secondary prevention of coronary heart disease
in postmenopausal women was recently published by Hulley
et al (791) for the Heart and Estrogen-Progestin Replace-
ment Study (HERS) Research Group. Contrary to con-
ventional wisdom and several observational studies (761–
764), this trial of 3763 postmenopausal women with
established coronary disease and an average age of 66.7
years found no reduction in overall risk for nonfatal MI
or coronary death, nor any other cardiovascular outcome,
during an average of 4.1 years of follow-up while taking
either 0.625 mg conjugated equine estrogen plus 2.5 mg
medroxyprogesterone acetate in 1 tablet daily (n 5 1380)
or placebo (n 5 1383).
This lack of an overall effect occurred despite a net 11%
lower low-density lipoprotein (LDL) cholesterol level and a
10% higher high-density lipoprotein (HDL) cholesterol in
the group given hormone therapy compared with the
placebo group (P , 0.001). There was a statistically signif-
icant time trend, however, with more primary coronary
events in the hormone therapy group than in the placebo
group in year 1 and fewer in years 4 and 5. More women in
the hormone group than in the placebo group experienced
venous thromboembolic events (34 versus 12; RR, 2.89;
95% CI, 1.50 to 5.58) and gallbladder disease (84 versus 62;
RR, 1.38; 95% CI, 1.00 to 1.92). On the basis of the finding
of no overall cardiovascular benefit and a pattern of early
increase in risk of coronary events, it was concluded that
starting estrogen plus progestin should not be recommended
for the purpose of secondary prevention of coronary disease
in postmenopausal women after an AMI. However, given
the favorable pattern of coronary events after several years of
therapy, it was considered appropriate for women already
receiving treatment to continue.
This study did not evaluate the cardiovascular effect of
treatment with unopposed estrogen, which is commonly
used in women who have had a hysterectomy, or other
estrogen plus progestin formulations. This study also did
not investigate women without coronary disease. Other
randomized trials of postmenopausal hormone therapy are
likely to answer some of the questions raised by HERS. The
Women’s Health Initiative Hormone Replacement Trial
(HRT) includes a group of women who have had hysterec-
tomies and received unopposed estrogen as well as women
with intact uteruses who receive the same estrogen plus
progestin used in HERS. Participants are not required to
have coronary heart disease and are generally younger than
those in the HERS cohort. The HRT has completed its
enrollment of 27,348 women and plans to report the results
of the trial in 2005 after 9 years of treatment.
The dose of estrogen for postmenopausal women who
have had a hysterectomy is usually 0.625 mg oral conjugated
estrogen or its equivalent once a day. In postmenopausal
women with a uterus, 2 dosing schedules are commonly
used: 0.625 mg conjugated estrogen or its equivalent once a
day plus 10 mg progestin (medroxyprogesterone) orally per
day for 10 to 14 days each month or 2.5 mg progestin orally
every day. Screening procedures for women without a uterus
who are taking estrogen are no different than for the
nontreated population. Women who take cyclic progestins
and develop bleeding other than at time of withdrawal or
women who take continuous progestin and develop heavy,
prolonged, frequent, or intermittent bleeding lasting .10
months after the start of progestin should be evaluated
(765).
There is overall uncertainty about the true benefit of
estrogen replacement therapy after MI in women. There-
fore, after careful counseling about the risk/benefit issues of
hormone replacement therapy, patient preference should be
the dominant factor in making any decision.
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ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction
1999 Update: Revisions and Additions to Recommendations
The following is a listing of the specific recommendations that have been revised:
JACC
page no.
CIRC
page no. Original Recommendation (1996) Revised Recommendation (1999)
1344 2344 Aspirin
Class IIb
1. Other antiplatelet agents such as dipyridamole
or ticlopidine may be substituted if true aspirin
allergy is present.
Aspirin
Class IIb
1. Other antiplatelet agents such as dipyridamole,
ticlopidine, or clopidogrel may be substituted if true
aspirin allergy is present or if the patient is
unresponsive to aspirin.
1348–49 2345 Primary PTCA
Class I
1. As an alternative to thrombolytic therapy only if
performed in a timely fashion by individuals
skilled in the procedure† and supported by
experienced personnel in high-volume centers.‡
Class IIa
1. As a reperfusion strategy in patients who are
candidates for reperfusion but who have a risk of
bleeding contraindication to thrombolytic
therapy (Table 3).
2. Patients in cardiogenic shock.
Class IIb
1. As a reperfusion strategy in patients who fail to
qualify for thrombolytic therapy for reasons
other than a risk of bleeding contraindication.
Class III
New.
Primary PTCA
Class I
1. As an alternative to thrombolytic therapy in patients
with AMI and ST-segment elevation or new or
presumed new LBBB who can undergo angioplasty
of the infarct-related artery within 12 hours of onset
of symptoms or beyond 12 hours if ischemic
symptoms persist, if performed in a timely fashion*
by persons skilled in the procedure† and supported by
experienced personnel in an appropriate laboratory
environment.‡
*Performance standard: balloon inflation within 90
(630) minutes of admission.
†Individuals who perform .75 PTCA procedures per
year.
‡Centers that perform .200 PTCA procedures per
year and have cardiac surgical capability (110).
2. In patients who are within 36 hours of an acute
ST-elevation/Q-wave or new LBBB MI who
develop cardiogenic shock are ,75 years old, and
revascularization can be performed within 18 hours
of onset of shock.
Class IIa
1. As a reperfusion strategy in candidates for
reperfusion who have a contraindication to
thrombolytic therapy (Table 3).
Class IIb
1. In patients with AMI who do not present with ST
elevation but who have reduced (less than TIMI
grade 2) flow of the infarct-related artery and when
angioplasty can be performed within 12 hours of
onset of symptoms.
Class III
This category applies to patients with AMI who
1. Undergo elective angioplasty of a non–infarct-
related artery at the time of AMI
2. Are beyond 12 hours after onset of symptoms
and have no evidence of myocardial ischemia
3. Have received fibrinolytic therapy and have no
symptoms of myocardial ischemia
4. Are eligible for thrombolysis and are undergoing
primary angioplasty performed by a low volume
operator in a laboratory without surgical capability
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page no.
CIRC
page no. Original Recommendation (1996) Revised Recommendation (1999)
1352 2345 Early Coronary Angiography and/or
Interventional Therapy
Class I
1. Patients with recurrent (stuttering) episodes of
spontaneous or induced ischemia or evidence of
shock, pulmonary congestion, or LV
dysfunction.
Class IIa
1. Patients with persistent ischemic-type
discomfort despite medical therapy and an
abnormal ECG or $2 risk factors for coronary
artery disease.
2. Patients with chest discomfort, hemodynamic
instability, and an abnormal ECG.
Class IIb
1. Patients with chest discomfort and an
unchanged ECG.
2. Patients with ischemic-type chest discomfort
and a normal ECG and .2 risk factors for
coronary artery disease.
Early Coronary Angiography and/or Interventional
Therapy
Class I
1. Patients with persistent or recurrent (stuttering)
episodes of symptomatic ischemia, spontaneous or
induced, with or without associated ECG changes.
2. Presence of shock, severe pulmonary congestion, or
continuing hypotension.
Class IIa
None.
Class IIb
None.
New New Glycoprotein IIb/IIIa Inhibitors
Class IIa
1. For use in patients experiencing an MI without ST-
segment elevation who have some high-risk features
and/or refractory ischemia, provided they do not
have a major contraindication due to a bleeding risk.
1368–69 2348 Emergency or Urgent Cardiac Repair of
Mechanical Defects
Class I
2. Postinfarction VSD or free wall rupture and
pulmonary edema or cardiogenic shock
(emergency or urgent).
Emergency or Urgent Cardiac Repair of Mechanical
Defects
Class I
2. Postinfarction VSD or free wall rupture.
1377–78 2348 Heparin
Class IIa
1. Intravenously in patients undergoing reperfusion
therapy with alteplase. Comment: The
recommended regimen is 70 U/kg as a bolus at
initiation of alteplase infusion, then an initial
maintenance dose of ’15 mg/kg per hour, adjusted
to maintain aPTT at 1.5 to 2.0 times control (50
to 75 seconds) for 48 hours (Table 9).
Continuation of heparin infusion beyond 48 hours
should be restricted to patients at high risk for
systemic or venous thromboembolism.
2. (new text)
Unfractionated Heparin
Class IIa
1. Intravenously in patients undergoing reperfusion
therapy with alteplase. Comment: The recommended
regimen is 60 U/kg as a bolus at initiation of alteplase
infusion, then an initial maintenance dose of ’12 U/
kg per hour (with a maximum of 4000 U bolus and
1000 U/h infusion for patients weighing .70 kg),
adjusted to maintain aPTT at 1.5 to 2.0 times control
(50 to 70 seconds) for 48 hours (Table 9).
Continuation of heparin infusion beyond 48 hours
should be considered in patients at high risk for systemic
or venous thromboembolism.
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3. Subcutaneously (7500 U twice daily)
(intravenous heparin is an acceptable alternative)
in all patients not treated with thrombolytic
therapy who do not have a contraindication to
heparin. In patients who are at high risk for
systemic emboli (large or anterior MI, AF,
previous embolus, or known LV thrombus),
intravenous heparin is preferred.
4. Intravenously in patients with nonselective
thrombolytic agents (streptokinase, anistreplase,
urokinase) who are at high risk for systemic
emboli (large or anterior MI, AF, previous
embolus, or known LV thrombus). Comment: It
is recommended that heparin be withheld for 4
hours and that aPTT testing begin at that time.
Heparin should be started when aPTT returns to
,2 times control (’70 seconds), then infused to
keep aPTT 1.5 to 2.0 times control (initial
infusion rate ’1000 U/h). After 48 hours, a
change to subcutaneous heparin, warfarin, or
aspirin alone should be considered.
2. Intravenous UFH or LMWH subcutaneously for
patients with non–ST-elevation MI.
3. Subcutaneous UFH (eg, 7500 U b.i.d.) or LMWH
(eg, enoxaparin 1 mg/kg b.i.d.) in all patients not
treated with thrombolytic therapy who do not have
a contraindication to heparin. In patients who are at
high risk for systemic emboli (large or anterior MI,
AF, previous embolus, or known LV thrombus),
intravenous heparin is preferred.
4. Intravenously in patients treated with nonselective
thrombolytic agents (streptokinase, anistreplase,
urokinase) who are at high risk for systemic emboli
(large or anterior MI, AF, previous embolus, or
known LV thrombus). Comment: It is recommended
that heparin be withheld for 6 hours and that aPTT
testing begin at that time. Heparin should be started
when aPTT returns to ,2 times control (’70
seconds), then infused to keep aPTT 1.5 to 2.0 times
control (initial infusion rate ’1000 U/h). After 48
hours, a change to subcutaneous heparin, warfarin, or
aspirin alone should be considered.
1381–82 2348 b-Adrenoceptor Blocking Agents
Early Therapy (see also “Predischarge
Preparation”)
Class I
1. Patients without a contraindication to b-
adrenoceptor blocker therapy who can be
treated within 12 hours of onset of infarction,
irrespective of administration of concomitant
thrombolytic therapy.
4. (new text)
Class IIb
1. Non–Q-wave MI.
Class III
1. Patients with moderate or severe LV failure or
other contraindications to b-adrenoceptor
blocker therapy.
b-Adrenoceptor Blocking Agents
Early Therapy
Class I
1. Patients without a contraindication to b-
adrenoceptor blocker therapy who can be treated
within 12 hours of onset of infarction, irrespective
of administration of concomitant thrombolytic
therapy or performance of primary angioplasty.
4. Non–ST-elevation MI.
Class IIb
1. Patients with moderate LV failure (the presence of
bibasilar rales without evidence of low cardiac
output) or other relative contraindications to b-
adrenoceptor blocker therapy, provided patients can
be monitored closely.
Class III
1. Patients with severe LV failure.
1382 2348 Angiotensin-Converting Enzyme Inhibitors
Class I
1. Patients within the first 24 hours of a suspected
AMI with ST-segment elevation in $2 anterior
precordial leads or with clinical heart failure in
the absence of significant hypotension or known
contraindications to use of ACE inhibitors.
Angiotensin-Converting Enzyme Inhibitors
Class I
1. Patients within the first 24 hours of a suspected
AMI with ST-segment elevation in $2 anterior
precordial leads or with clinical heart failure in the
absence of hypotension (systolic BP ,100 mm Hg)
or known contraindications to use of ACE
inhibitors.
1395 2349–50 Management of Lipids
Class IIb
1. Drug therapy using either niacin or gemfibrozil
may be added to diet regardless of LDL and
HDL levels when triglyceride levels are .400
mg/dL.
Management of Lipids
Class IIb
1. Drug therapy with either niacin or gemfibrozil may
be added to diet regardless of LDL and HDL levels
when triglyceride levels are .200 mg/dL.
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1397 2350 b-Adrenoceptor Blockers
Long-Term Therapy in Survivors of Myocardial
Infarction
Class IIa
2. (new text)
(Class IIb New.)
Class III
1. Patients with a contraindication to b-
adrenoceptor blocker therapy.
b-Blocker
Long-Term Therapy in Survivors of Myocardial
Infarction
Class IIa
2. Survivors of non–ST-elevation MI.
Class IIb
1. Patients with moderate or severe LV failure or other
relative contraindication to b-adrenoceptor blocker
therapy, provided patients can be monitored closely.
Class III
None.
1399 2350 Estrogen Replacement Therapy and Myocardial
Infarction
Class IIa
1. All postmenopausal patients who have an MI
should be carefully counseled about the
potential beneficial effects of ERT and offered
the option of ERT if they desire it.
Estrogen Replacement Therapy and Myocardial
Infarction
Class IIa
1. HRT with estrogen plus progestin for secondary
prevention of coronary events should not be given
de novo to postmenopausal women after AMI.
2. Postmenopausal women who are already taking
HRT with estrogen plus progestin at the time of
AMI can continue this therapy.
ACE 5 angiotensin-converting enzyme, AF 5 atrial fibrillation, AMI 5 acute myocardial infarction, BP 5 blood pressure, Circ 5 Circulation, ECG 5 electrocardiogram,
ERT 5 estrogen replacement therapy, HDL 5 high-density lipoprotein, HRT 5 hormone replacement therapy, JACC 5 Journal of American College of Cardiology, LBBB 5
left bundle-branch block, LDL 5 low-density lipoprotein, LMWH 5 low-molecular-weight heparin, LV 5 left ventricular, PTCA 5 percutaneous transluminal coronary
angioplasty, TIMI 5 Thrombolysis in Myocardial Infarction, UFH 5 unfractionated heparin, VSD 5 ventricular septal defect.
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